0HKD.LSE Axogen Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -5.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0HKD.LSE undervalued?
Graham numberThe Graham number of Axogen Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Axogen Inc. fundamental analysis
No fundamental analysis for Axogen Inc. yet.
Axogen Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Axogen Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product us…
Full company profileAxogen Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Axogen Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 41.1M | 60.4M | 83.9M | 107M | 112M | 127M | 139M | 159M | 187M | 225M | 276M |
| Gross Profit | 34.6M | 51.1M | 71.0M | 89.4M | 90.7M | 104M | 114M | 128M | 142M | 167M | 205M |
| Operating Income | -8.13M | -7.95M | -20.5M | -28.9M | -23.2M | -25.4M | -29.7M | -21.5M | -3.29M | -7.85M | -5.38M |
| EBITDA | -7.69M | -7.42M | -19.6M | -26.2M | -19.3M | -20.9M | -23.5M | -15.9M | 6.08M | 659K | 2.00M |
| Net Income | -14.4M | -10.4M | -22.4M | -29.1M | -23.8M | -27.0M | -28.9M | -21.7M | -9.96M | -15.7M | -25.0M |
| EPS | -0.47 | -0.31 | -0.60 | -0.74 | -0.60 | -0.65 | -0.69 | -0.51 | -0.23 | -0.34 | -0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 46.4M | 58.9M | 160M | 155M | 201M | 208M | 195M | 197M | 204M | 222M | 550M |
| Total Liabilities | 31.4M | 33.7M | 13.2M | 22.5M | 78.2M | 95.5M | 94.4M | 101M | 99.8M | 92.8M | 54.2M |
| Shareholders' Equity | 14.9M | 25.2M | 147M | 132M | 123M | 113M | 101M | 95.7M | 104M | 129M | 496M |
| Cash & Short-term Investments | 30.0M | 36.5M | 123M | 103M | 111M | 90.3M | 55.0M | 31.0M | 39.5M | 45.5M | 350M |
| Total Debt | 24.3M | 24.6M | 63.0K | 3.33M | 53.8M | 67.5M | 67.4M | 72.3M | 68.7M | 88.4M | 19.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -11.2M | -9.24M | -17.9M | -19.9M | -9.63M | -13.4M | -16.1M | -5.72M | 4.54M | 2.75M | 38.3M |
| Capital Expenditure | 1.19M | 1.29M | 6.60M | 5.23M | 22.6M | 28.4M | 21.3M | 13.9M | 3.10M | 3.75M | 6.77M |
| Free Cash Flow | -12.4M | -10.5M | -24.5M | -25.1M | -32.2M | -41.8M | -37.3M | -19.6M | 1.43M | -996K | 31.5M |
| Ratios | |||||||||||
| ROE | -96.6% | -41.5% | -15.2% | -22.0% | -19.3% | -24.0% | -28.7% | -22.7% | -9.6% | -12.2% | -5.0% |
| ROA | -31.1% | -17.7% | -14.0% | -18.8% | -11.8% | -13.0% | -14.8% | -11.0% | -4.9% | -7.1% | -4.5% |
| Net Profit Margin | -35.1% | -17.3% | -26.7% | -27.3% | -21.2% | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% | -9.1% |
| Debt to Equity | 1.63x | 0.98x | 0.00x | 0.03x | 0.44x | 0.60x | 0.67x | 0.76x | 0.66x | 0.69x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Axogen Inc. dividends
Axogen Inc. has not paid dividends in the last 9 fiscal years.
Who owns Axogen Inc.
- Insiders 1.94%
- Institutions 96.19%
- Public & others 1.87%
- Free float 54.6M
Axogen Inc. company profile
- Company name
- Axogen Inc.
- Ticker
- 0HKD.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 622
- Fiscal year end
- December
- Address
- 13631 Progress Boulevard, Alachua, FL, United States, 32615
- Phone
- 386 462 6800
- Website
- axogeninc.com
About Axogen Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Axogen Inc. management
10- Mr. Michael D. DalePresident, CEO & Director · born 1960
- Ms. Lindsey Hartley CPAChief Financial Officer
- Mr. Erick DeVinneyChief Scientific Officer · born 1976
- Mr. Marc A. BeganExecutive VP, General Counsel, Secretary & Chief Compliance Officer · born 1968
- Mr. Jens Schroeder KempChief Marketing Officer · born 1977
- Ms. Paris DallyVice President of Operations
- Mr. Harold D. Tamayo M.B.A.Vice President of Finance & Investor Relations
- Dr. Ivica Ducic M.D., Ph.D.Chief Medical Officer
- Ms. Doris QuackenbushChief Revenue Officer
- Mr. Rick DittoVice President of Global Health Economics, Reimbursement & Policy